New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 7, 2012
10:05 EDTAET, RHHBY, MCD, DST, SYT, AKR, ATHN, TSM, MPELOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Acadia Realty Trust (AKR) upgraded to Outperform from Market Perform at BMO Capital... McDonald's (MCD) upgraded to Buy from Neutral at Janney Capital... Melco Crown (MPEL) upgraded to Overweight from Neutral at JPMorgan... Syngenta (SYT) upgraded to Neutral from Underweight at JPMorgan...Roche (RHHBY) upgraded to Overweight from Equal Weight at Morgan Stanley... TSMC (TSM) upgraded to Outperform from Neutral at Credit Suisse... DST Systems (DST) upgraded to Buy from Neutral at Sterne Agee... Aetna (AET) upgraded to Overweight from Neutral at JPMorgan... athenahealth (ATHN) upgraded to Outperform from Market Perform at Leerink.
News For AKR;MCD;MPEL;SYT;RHHBY;TSM;DST;AET;ATHN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
March 18, 2015
12:48 EDTRHHBYFly Watch: Biogen predicted to report strong Alzheimer's data this Friday
Subscribe for More Information
12:46 EDTAETAetna, HackensackAlliance ACO announce collaboration
Subscribe for More Information
07:46 EDTRHHBYLilly Roche would have upbeat read through from strong BIIB data, says Bernstein
Bernstein notes that the data for Biogen's (BIIB) Alzheimer's treatment, due to be released on Friday, is widely expected to be positive. The firm thinks that positive data would boost the outlook for similar Alzheimer's drugs being developed by Eli Lilly (LLY) and Roche (RHHBY), since consensus estimates for those drugs are low. The firm keeps Outperform ratings on Eli Lilly and Roche.
March 17, 2015
09:00 EDTAETAetna management to meet with JPMorgan
Subscribe for More Information
08:13 EDTRHHBYCelldex announces clinical trial collaboration with Roche
Celldex Therapeutics (CLDX) announced that it has entered into a clinical trial collaboration with Roche (RHHBY) to evaluate the safety, tolerability and preliminary efficacy of varlilumab, Celldex's CD27 targeting investigational antibody, and MPDL3280A, Roche's investigational cancer immunotherapy in a Phase 1/2 study in renal cell carcinoma. Varlilumab and MPDL3280A are part of a new class of investigational medicines known as cancer immunotherapies that are designed to harness the body's own immune system to fight cancer through separate yet complementary mechanisms of action that may enable the activation of T cells, restoring their ability to effectively detect and attack tumor cells. Preclinical data suggest the combination of these two mechanisms are synergistic and may enhance anti-tumor immune response compared to either agent alone. In Celldex's Phase 1 study of varlilumab in multiple solid tumors, promising signs of clinical activity in patients with refractory renal cell carcinoma were observed, including a durable partial response that has continued to decrease in tumor volume over time and prolonged stable disease. Under the terms of this agreement, Roche will provide study drug and Celldex will be responsible for conducting and funding the study, which is expected to begin in 2015.
06:46 EDTMCDMcDonald's burn complaints to focus on corporate reponsibility, WSJ says
Subscribe for More Information
06:06 EDTMCDMcDonald's employees file complaints of burns, injuries, LA Times says
McDonald's employees have filed complaints against 28 McDonald's locations -- including nine owned by the corporation itself -- alleging they received burns on the job, reports the LA Times, citing statements by union-backed group Fast Food Forward. The complaints were lodged with the Occupational Safety and Health Administration and claim that greasy floors, lack of staff, and an extremely fast-paced environment elevate the risk of injury in McDonald's restaurants. Reference Link
March 16, 2015
10:02 EDTMPELOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:04 EDTMPELMelco Crown downgraded to Equal Weight from Overweight at Morgan Stanley
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use